%0 Journal Article
%T Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
%A Makoto Nakamura
%A Masashi Kimura
%A Mizuki Tagami
%A Sentaro Kusuhara
%J Archive of "Case Reports in Ophthalmology".
%D 2019
%R 10.1159/000496197
%X Axitinib, an orally administered vascular endothelial growth factor receptors 1, 2, and 3 inhibitor, is widely used as the second-line treatment for metastatic renal cell carcinoma. We present a case of metastatic renal cell carcinoma who developed a novel ocular adverse event, impaired retinal circulation, during axitinib therapy
%K Adverse event
%K Axitinib
%K Renal cell carcinoma
%K Retinal circulation
%K Vascular endothelial growth factor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489367/